Effect of febuxostat on clinical outcomes in patients with hyperuricemia and cardiovascular disease
Masaaki Konishi(Yokohama City University Medical Center), Hisao Ogawa(Kumamoto University Hospital), Shinya Hiramitsu(Nagoya Heart Center), Kunihiko Matsui(Kumamoto University), Kazuo Kimura(Yokohama City University Medical Center), Kazuaki Uchiyama, Ichiro Hisatome(National Institute of Technology, Yonago College), Hideaki Jinnouchi, Masako Waki(Shizuoka City Hospital), Hisao Mori, Hirokazu Kakuda, Naoki Kawai, Yoshihiko Saito(National Archives and Records Administration), Eiichi Tokutake, Sunao Kojima(Kumamoto University), Takahiro Hayashi, Naoto Yokota, Yusuke Ohya(University of the Ryukyus), Yutaka Wakasa(Kanazawa Medical Center), Masahiro Sugawara(Nerima General Hospital), Kenichi Tsujita(Kumamoto University)
Cited by 38
Related Papers
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
|New England Journal of Medicine|2017|9.1k
Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial
|The Lancet|2017|1.3k
Thrombin-Receptor Antagonist Vorapaxar in Acute Coronary Syndromes
|New England Journal of Medicine|2011|753
Impact of Dual Lipid-Lowering Strategy With Ezetimibe and Atorvastatin on Coronary Plaque Regression in Patients With Percutaneous Coronary Intervention
|Journal of the American College of Cardiology|2015|449